We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advises on Endpoints, Patients In Early-Stage Alzheimer’s Trials
FDA Advises on Endpoints, Patients In Early-Stage Alzheimer’s Trials
February 13, 2013
FDA draft guidance on early-stage Alzheimer’s drugs offers tips on endpoint selection, patient selection and showing disease modification.